Could COVID-19 Variants Upend Global Vaccine Supply Deals?
WHO Approval Softens South Africa Blow For AZ Partner
South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?
You may also be interested in...
As vaccine makers tackle SARS-CoV-2 variants, WHO’s Chief Scientist feels it’s important to continue immunization programs with existing vaccines. Meanwhile, the rollouts mean the safety and efficacy landscape is set to change, said participants at a recent meet
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.
South Korea approves AstraZeneca’s COVID-19 Vaccine, while Actemra moves forward in Japan after local study results.